GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » General and Admin. Expense

Incyte (BSP:I1NC34) General and Admin. Expense : R$6,187 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Incyte General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Incyte's General and Admin. Expense for the three months ended in Sep. 2024 was R$1,712 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024 was R$6,187 Mil.

Incyte General and Admin. Expense Historical Data

The historical data trend for Incyte's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte General and Admin. Expense Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2,659.30 4,182.36 5,256.42 5,690.14

Incyte Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,323.08 1,440.05 1,495.43 1,539.35 1,712.29

Incyte General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$6,187 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Incyte's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » General and Admin. Expense
Comparable Companies
SMMT INSM BMRN MRNA RPRX TECH PCVX UTHR SRPT EXEL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
INCY:USA INCY:Mexico 1INCY:Italy 0J9P:UK ICY:Germany
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Website
https://www.incyte.com
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines